尼沃卢马布加布伦图西马布维多丁治疗复发性/耐火性扩散性大B细胞淋巴瘤
Nathalie A Johnson1, Pier Luigi Zinzani2,3, Eva Domingo-Domenech4
1Department of Medicine, Division of Hematology, Jewish General Hospital, Montreal, QC, Canada.
尼沃卢马布加布伦图西马布维多丁在复发性/耐火性扩散性大B细胞淋巴瘤 (DLBCL) 中显示出有限的疗效. 该组合没有满足主要终点,表明它不是R/R DLBCL的可行的治疗选择.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 在初始治疗后复发或折射率 (R/R) 高.
- 对于R/R DLBCL患者的结果很差,特别是在血造干细胞移植失败后.
研究的目的:
- 评估PD-1/PD-L1抑制剂尼沃卢马布与布伦图西马布维多丁 (BV) 结合的疗效和安全性.
- 在CheckMate 436 1/2期研究中评估R/R DLBCL患者的治疗.
主要方法:
- 患有R/R DLBCL的成年患者在3周周期内接受了尼沃卢马布加BV.
- 主要终点是整体反应率 (ORR).
- 报告了R/R DLBCL队列 (n=42) 的结果,随访时间中位数为7.7个月.
主要成果:
- 总体应答率 (ORR) 为28.6% (12/42名患者),其中7.1% (3/42) 达到完全应答.
- 响应的平均持续时间为3.6个月.
- 所有患者都经历了不良事件 (AE),腹是最常见的 (47.6%). 在57.1%的患者中发生了3/4级AE,9.5%的患者经历了5级AE.
结论:
- 在R/R DLBCL中,尼沃卢马布加布伦图西马布维多丁的疗效没有达到预期.
- 根据CheckMate 436研究结果,组合疗法不支持其用于治疗R/R DLBCL.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
相关概念视频
Treatment Resistant Cancers
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
